Emcure Pharmaceuticals Outlines Strong FY26 Growth and Multi-Vector Strategic Expansion
Emcure Pharmaceuticals Ltd 路 Investor Presentation 路 25 Sept 2026, 10:06 pm
Emcure Pharmaceuticals Outlines Strong FY26 Growth and Multi-Vector Strategic Expansion Emcure Pharmaceuticals reported FY26 revenue of INR 92,035 Mn (+16.6% YoY) and PAT of INR 9,413 Mn (+33.1% YoY), driven by EBITDA margin expansion to 19.4% and RoCE reaching 23.7%. International revenue rose 22.2% YoY to INR 51,766 Mn, while domestic formulations grew 10.0% YoY to INR 40,270 Mn with chronic mix crossing 60%. In Q1 FY27, revenue climbed 22.8% YoY to INR 25,804 Mn and PAT surged 36.2% YoY to INR 2,925 Mn. Emcure targets FY26鈥揊Y30 growth via complex injectables, biologics, and in-licensing deals.
Original exchange filing (PDF)
More announcements from Emcure Pharmaceuticals Ltd
- Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026 路 15 Nov 2026
- Transcript of Earnings Call - Q2 FY27 held on Tuesday, November 03, 2026 at 4:00 p.m. (IST) 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026 路 06 Nov 2026
- Audio recording of Earnings Call - Q2 FY27 路 04 Nov 2026
- Presentation on Unaudited Financial Results for the quarter ended September 30, 2026 路 03 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026 路 03 Nov 2026
- Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 03 Nov 2026
